Scribe Therapeutics prices its Nasdaq IPO (SCTX), kicking off a wave of six biotechs expected to go public in the coming weeks.
Benjamin Oakes, Scribe Therapeutics CEO
July 23, 2026 10:01 PM EDT
Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing
A 9-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year’s second half.
Scribe Therapeutics …
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other…
Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of…
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go…
Scribe markets its Nasdaq IPO at a $14 midpoint for ~$96M net proceeds; Scholar Rock's apitegromab awaits an FDA call on Novo…
A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a…
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in…
